# Kala BIO, Inc. (KALA)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001479419 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001479419))
- Full page: https://inspectstocks.com/stocks/kala
- Data as of: price 2026-09-28; newest filing used 2026-08-19; latest fiscal period ended 2026-06-30

## Grade

**F** on the balance-sheet rubric used for lenders, 1 of 5 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | failed | -$10.1M |  |
| Earnings growing overall | failed | -$10.1M | -$8.6M |
| Earnings growing recently | passed | -$10.1M | -$27M |
| Earns well on its assets | failed | -95.3% |  |
| Book value per share growing | failed | $0.86 | $12.48 |

Business quality (the + / − mark): 0 of 2 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Good return on equity | failed | -144.1% |  |
| Debt under control | failed | 4.61 |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $0.00 |
| Net income, trailing twelve months | -$10.1M |
| Return on equity | -144.1% |
| Debt to equity | 4.61 |
| Diluted EPS, trailing twelve months | -$3.31 |
| Share price | $0.46 |
| Market value | $8.8M |

## More on this company

- [Overview](https://inspectstocks.com/stocks/kala)
- [Financial statements](https://inspectstocks.com/stocks/kala/financials)
- [Competitors](https://inspectstocks.com/stocks/kala/peers)
- [Earnings](https://inspectstocks.com/stocks/kala/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.